Funded K01 Grants

Frequently Asked Questions

Policy-Related Policy/Post Award

NCI Staff Contacts

Introduction

We are no longer accepting new or revised applications for the Howard Temin K01 award. Please consider an application for the Howard Temin Pathway to Independence Award in Cancer Research (K99/R00).

You may still access the Howard Temin K01 Program Announcement at: PAR-03-104 THE HOWARD TEMIN AWARD (K01)

Back to Top Funded K01 Grants

Grant #	PI Name	Project Title	Org Name
5K01CA094987-05	AMERIK, ALEXANDER YU	The Role of Doa4 in Membrane Protein Trafficking	UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
5K01CA100736-05	ANGELETTI, PETER C.	Maintenance of Human Papillomavirus Genomes	UNIVERSITY OF NEBRASKA LINCOLN
5K01CA095620-05	AYYANATHAN, KASIRAJAN	Role of SNAG Corepressors in Repression and Oncogenesis	FLORIDA ATLANTIC UNIVERSITY
5K01CA093855-06	BACHELDER, ROBIN E	Novel function for VEGF in breast carcinoma survival	DUKE UNIVERSITY
5K01CA104647-03	BARDEESY, NABEEL	Mouse Model of Pancreatic Cancer Progression-Maintenance	MASSACHUSETTS GENERAL HOSPITAL
7K01CA118259-02	Bernardi, Rosa	Regulation of HIF-1 and tumor angiogenesis by PML and PML-RARa	BETH ISRAEL DEACONESS MEDICAL CENTER
5K01CA118732-02	BIELENBERG, DIANE R	Semaphorin 3F: Structure, Function, and Anti-Metastatic Activity	CHILDREN'S HOSPITAL BOSTON
5K01CA117985-02	Blattman, Joseph N	Enhancing CD8 T Cell Function by Abrogating Inhibition by Regulatory Proteins	UNIVERSITY OF WASHINGTON
7K01CA123142-02	Chandra, Dhyan	Novel Insight on Nucleotide Regulation of Apoptosome Activation	ROSWELL PARK CANCER INSTITUTE CORP
5K01CA096774-05	CHEN, XIN	Gene Expression Profiles in Human Liver Cancers	UNIVERSITY OF CALIFORNIA SAN FRANCISCO
5K01CA098320-05	CHENG, EMILY H	Regulation of BAX/BAK-Dependent Cell Death	WASHINGTON UNIVERSITY
5K01CA115917-02	Cho, Hearn J	Type 1 MAGE vaccine immunotherapy for multiple myeloma	NEW YORK UNIVERSITY SCHOOL OF MEDICINE
5K01CA104706-04	COCHRAN, JENNIFER R	Engineering high affinity integrin binding proteins	STANFORD UNIVERSITY
5K01CA122183-02	Collier, Lara S	Sleeping Beauty for cancer gene discovery	UNIVERSITY OF MINNESOTA TWIN CITIES
5K01CA094907-05	COOK, JEANETTE G	Pre-replication complex formation in mammalian cells	UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
5K01CA106596-04	DANIAL, NIKA N	BAD Intergrates Glycolysis and Apoptosis	DANA-FARBER CANCER INSTITUTE
5K01CA098090-05	DANIEL, RENE	Cellular Response to Retroviral DNA Integration	THOMAS JEFFERSON UNIVERSITY
1K01CA125051-01	DELUCA, JENNIFER G	The Kinetochore-Microtubule Interface in Vertebrate Cells	COLORADO STATE UNIVERSITY-FORT COLLINS
5K01CA111818-04	DEMALI, KRIS A	Role of Vinculin in Epithelial Cell Junctions	UNIVERSITY OF IOWA
1K01CA124461-01	DENG, YIBIN	Telomere dysfunction, p53 and tumorigenesis	UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
5K01CA113838-03	DEVIREDDY, LAXMINARAYANA R	Role of Lipocalin 24p3 in Apoptosis and Leukemia	CASE WESTERN RESERVE UNIVERSITY
5K01CA114252-03	DONG, YAN	ANDROGEN RECEPTOR SIGNALING IN SELENIUM CHEMOPREVENTION	ROSWELL PARK CANCER INSTITUTE CORP
5K01CA097283-04	DURRIN, LINDA K	SATB1-protein Interaction/function at the BcL2 mbr/MAR	CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
5K01CA105050-03	ELMORE, LYNNE W	Genomic Instability and Senescence in Cancer	VIRGINIA COMMONWEALTH UNIVERSITY
5K01CA093660-06	FAN, HUA-YING	Functional Analysis of SWI/SNF chromatin remodelers	INSTITUTE FOR CANCER RESEARCH
5K01CA092156-06	FRAUWIRTH, KENNETH A	Signaling Pathways for Anergy Induction and Maintenance	UNIVERSITY OF MARYLAND COLLEGE PK CAMPUS
5K01CA111623-03	Frost, Patrick J	Effects of mTOR inhibitors on multiple myeloma tumors	BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
5K01CA109238-04	GANESAN, SHRIDAR	BRCA1 AND X CHROMOSOME INACTIVATION	UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
5K01CA102098-05	GAO, TIANYAN	Phosphatase mediated regulation of PKC and Akt	UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
5K01CA090414-05	GIZACHEW, DAWIT	NMR studies of the structure of myristylated Arf6	CORNELL UNIVERSITY ITHACA
5K01CA117982-02	GLAUNSINGER, BRITT A	Shutoff of cellular gene expression by Kaposi's sarcoma-associated herpesvirus	UNIVERSITY OF CALIFORNIA BERKELEY
5K01CA111343-03	GOODRUM, FELICIA D	Human Cytomegalovirus Latency in Hematopoietic Cells	UNIVERSITY OF ARIZONA
7K01CA118425-02	Haigis, Kevin	Genetic and genomic analysis of Ras signaling in colorectal cancer progression	MASSACHUSETTS GENERAL HOSPITAL
5K01CA095582-04	HARTON, JONATHAN A	Molecular Regulation of CIITA Function by GTP-Binding	ALBANY MEDICAL COLLEGE
5K01CA101777-04	HODGSON, JOHN G	Discovery and characterization of breast cancer genes	UNIVERSITY OF CALIFORNIA SAN FRANCISCO
5K01CA102594-05	HSIEH, JAMES J-D	Genetic and Biochemical Analyses of MLL Cleavage	WASHINGTON UNIVERSITY
1K01CA114027-01A2	KAI, MIHOKO	Role of the Checkpoint in Maintaining Genome Stability	STANFORD UNIVERSITY
7K01CA098176-03	Kandel, Eugene	Genetic Determinants of Akt-induced Transformation	ROSWELL PARK CANCER INSTITUTE CORP
1K01CA118722-01A1	KANG-DECKER, NINGLING	Mechanism of nitric oxide inhibition of pericyte recruitment in liver tumors	MAYO CLINIC COLL OF MEDICINE, ROCHESTER
5K01CA115681-03	KIM, SUWON	Roles for ING4 as a tumor suppressor in breast cancer	UNIVERSITY OF ARIZONA
5K01CA114400-03	Knoepfler, Paul S	Analyzing Myc function in neural cancers and development	UNIVERSITY OF CALIFORNIA DAVIS
5K01CA100764-05	KNUTSON, KEITH L	Ex vivo expansion of HER-2/neu specific T helper cells	MAYO CLINIC COLL OF MEDICINE, ROCHESTER
5K01CA099156-05	LACORAZZA, HUGO Daniel	Regulation of Innate Immunity and Hematopoiesis by MEF	BAYLOR COLLEGE OF MEDICINE
5K01CA106599-04	Li, Chi	Regulation of apoptosis by Bcl-XL, Bak and Bax	UNIVERSITY OF LOUISVILLE
5K01CA096706-05	LI, RENHAO	Structure and function of integrin TM and CYTO domains	UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
5K01CA107092-04	LINDENBACH, BRETT D	Hepatocellular carcinoma: targeting HCV replication	YALE UNIVERSITY
5K01CA114313-02	Liu, Tian	Ultrasonic Tissue-Typing-Guided Prostate Brachytherapy	COLUMBIA UNIVERSITY HEALTH SCIENCES
5K01CA114401-03	LIU, XIAOQI	Functional studies of Plk1 and its interacting proteins	PURDUE UNIVERSITY WEST LAFAYETTE
5K01CA118423-02	Lo, Hui-Wen	Nuclear EGFR Signaling Network in Human Cancer	DUKE UNIVERSITY
5K01CA100292-05	LUO, XUELIAN	Structure and function of the Mad2 checkpoint protein	UNIVERSITY OF TEXAS SW MED CTR/DALLAS
5K01CA119107-02	MARINTCHEV, ASSEN G	Regulation of translation through the human translation initiation factor eIF5B	HARVARD UNIVERSITY (MEDICAL SCHOOL)
5K01CA096555-05	MARTIN, STUART S	Actin-regulated Apoptosis in Mammary Tumorigenesis	UNIVERSITY OF MARYLAND BALTIMORE
5K01CA111723-02	MCALLISTER, SEAN D	Control of Breast Cancer by the Endocannabinoid System	CALIFORNIA PACIFIC MED CTR RES INSTITUTE
5K01CA100095-05	MENAA, CHEIKH	Molecular Mechanism of Tumor-Osteoclast Interactions	EVANSTON NORTHWESTERN HEALTHCARE
5K01CA111633-02	MEYN, MALCOLM A	Regulation of Tumor Cell Differentiation by Src Kinases	UNIVERSITY OF PITTSBURGH AT PITTSBURGH
5K01CA122822-02	Morgan, Kelly	Oncogenic potential of stem cells isolated from fetal liver vs adult bone marrow	BRIGHAM AND WOMEN'S HOSPITAL
5K01CA118174-03	NAHTA, RITA	HER-2/IGF-IR cross-talk and Herceptin resistance	EMORY UNIVERSITY
1K01CA122192-01A1	PEDERSEN, IRENE M	Cooperation of PTEN and SHIP as tumor suppressors in B-Cells	UNIVERSITY OF CALIFORNIA SAN DIEGO
5K01CA098743-06	PLAS, DAVID R	Regulation of Cellular Survival, Size and Metabolism	UNIVERSITY OF CINCINNATI
5K01CA118731-02	PODSYPANINA, KATRINA	Multiple mutations in tumor maintenance	SLOAN-KETTERING INSTITUTE FOR CANCER RES
5K01CA111402-02	PRINS, ROBERT M	Immune targeting of melanoma-associated antigens in glioma	UNIVERSITY OF CALIFORNIA LOS ANGELES
5K01CA098330-06	REUTHER, GARY W	Oncogenes involved in acute myeloid leukemia development	H. LEE MOFFITT CANCER CTR & RES INST
5K01CA113367-02	ROOSE, JEROEN P	The role of tonic signal-input in stable gene profiles	UNIVERSITY OF CALIFORNIA SAN FRANCISCO
5K01CA096664-05	Rosenfeld, Cheryl	Interferon and Raloxifene Effects on Cancer Cells	UNIVERSITY OF MISSOURI-COLUMBIA
5K01CA113779-02	Ryu, Byungwoo	Development of Novel Markers for Melanoma Progression	JOHNS HOPKINS UNIVERSITY
5K01CA098809-05	SANG, NIANLI	Transactivating of Activity of HIF-1 in tumorigenesis	THOMAS JEFFERSON UNIVERSITY
5K01CA109567-02	Savellano, Mark David	New Strategies for Photoimmunodetection/therapy	DARTMOUTH COLLEGE
5K01CA104700-03	SETH, PANKAJ K	MAGIC ROUNDABOUT (MRB), A TUMOR ENDOTHELIAL MARKER	BETH ISRAEL DEACONESS MEDICAL CENTER
5K01CA098316-05	SHERWOOD, DAVID R	Analysis of Cell Invasive Behavior in C. elegans	DUKE UNIVERSITY
5K01CA096618-05	SWANSON, MARK G	HR-MAS-pathologic correlation of prostate tissue markers	UNIVERSITY OF CALIFORNIA SAN FRANCISCO
5K01CA115679-04	TONG, WEI	Mechanism of Lnk function in cytokin receptor signaling	CHILDREN'S HOSPITAL OF PHILADELPHIA
5K01CA116275-03	WANG, BIN	DNA damage signaling and repair in mammalian cells	BRIGHAM AND WOMEN'S HOSPITAL
5K01CA116002-03	WU, JENNIFER D	Modeling MIC Shedding in Prostate Cancer Progression	UNIVERSITY OF WASHINGTON
5K01CA102328-05	Wu, Lizhao	Tumor Suppressor and Oncogenic Pathways in the Placenta	UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
1K01CA124856-01	Xing, Yongna	Structural and Systematic Biology of PP2A and Cancer Treatment.	PRINCETON UNIVERSITY
5K01CA114033-02	YI, YAJUN	Identifying Metastasis-Suppressor Genes in Cancer	VANDERBILT UNIVERSITY
5K01CA101957-05	YU, DONG	Global genetic analysis of the human cytomegalovirus	WASHINGTON UNIVERSITY
5K01CA098581-05	ZENG, HUIYAN	Expression and Function of TR3/nur77 in angiogenesis	BETH ISRAEL DEACONESS MEDICAL CENTER
5K01CA120099-03	ZHANG, CHENGCHENG	Expansion of hematopoietic stem cells by Angiopoietin-like 2	UNIVERSITY OF TEXAS SW MED CTR/DALLAS
7K01CA120144-02	ZHANG, JING	Oncogenic K-ras/downstream signaling pathways in hematopoietic progenitors	UNIVERSITY OF WISCONSIN MADISON
5K01CA123532-02	ZHAO, HONGJUAN	Identification, Isolation and Characterization of Prostate Cancer Stem Cells	STANFORD UNIVERSITY
1K01CA120711-01A1	Zijlstra, Andries	The molecular mechanisms of migration of which lead to tumor cell intravasation.	VANDERBILT UNIVERSITY
5K01CA098092-04	ZONG, WEI-XING	Bcl-2 family proteins in the ER-mediated apoptosis	STATE UNIVERSITY NEW YORK STONY BROOK

Back to Top Frequently Asked Questions

Policy-Related

1. Can the career awardee stay at his/her current institution in an unmentored phase?
Yes. The NCI Staff must approve the transition to an unmentored phase at the same institution in the same way as if they were moving to another institution. The career awardee must show that he/she is independent of the mentor and performing as an independent researcher. The institution must demonstrate that this is a suitable position for the applicant to conduct independent research.

2. Should the career awardee apply for other support (R01, R03, R21) immediately after change of phase from mentored to unmentored?
There is no specific requirement as to when an individual should apply for independent research support. However, it is important that the career awardee become fully independent as soon as possible, and gaining independent funding is a major step to fully implement the purpose of this award.

3. If the career awardee changes institutions during the mentored phase of the award must he/she designate a new sponsor?
Yes. The NCI must approve the transfer from one mentor to another as well as a change of institution. This, however, is not recommended since the success of your application in peer review was based significantly on the sponsor's research environment and ability to provide mentorship.

4. If a career awardee changes from a mentored to unmentored phase, will the salary remain the same?
A change of institution or status may result in a change of salary. The new salary must be consistent with the established salary of other members of equivalent qualifications, rank and responsibilities in the organization. The institution may request up to $75,000 per year, plus fringe benefits, and commit to the career awardee a minimum of 75% full-time professional effort to conduct research and research career development. There will be a change in the Research Development support. During the mentored phase $30,000 will be provided for the career awardee. The amount will increase to $50,000 per year when he/she moves to an unmentored, independent research environment. These changes must be built into the original budget, not negotiated at the time of transition.

5. Can I apply for a research grant from the PHS and still keep my career development award?
Yes, however the rules regarding salaries have changed as of 2/1/04 (NOT-OD-04-007). Please contact NCI staff for your particular situation.

6. If I submit a research grant application (e.g., R01) after receiving a Career Development Award, how does the NCI reconcile the percent level of effort commitment and salary on the research grant application with the requirements of the Career Development Award?
The total percent level of effort commitment on the Career Award and the research grant cannot exceed 100 percent. The percent effort commitment permitted on the research grant will be negotiated at the time of award and will depend on the degree of overlap between the specific aims of the two funding sources. (Please contact the NCI Staff Contacts for the Career Award for additional detailed information on this issue.)

Policy/Post Award

7. What is the minimum time after award of the K01 that the career awardee (Principal Investigator) must remain in the mentored phase?
The career awardee must spend at least one year, but not more than three years, in the mentored phase. The awardee and the mentor must agree when the change of phase will occur. The NCI Program Director must be notified well in advance of this transition.

8. What is considered a suitable position for the independent phase of the award?
The NCI believes that a tenure track position at a level reflective of the accomplishments and responsibilities of the career awardee is most appropriate. The NCI program staff will carefully review these aspects:

• Resources offered to career awardee for independent research program;
• Stability of position, e.g., tenure track or equivalent; and
• Clear commitment for protective time to develop research program.

9. If I have a K01 award and would like to ask for post award changes, how do I go about this?
You must contact the NCI Grants Administration official to determine the appropriate procedures to use in making a request for post award changes in your grant. This also applies to any of your needs that require a prior approval from the NCI. In general, you will have to make a request that is signed by you and a business official of your institution. After receiving the request, the Grants Administration official will consult with the NCI scientific program staff as necessary to determine whether the request can be approved.

Back to Top NCI Staff Contacts

For additional information regarding policies and/or guidance in preparing an application for the K01 Award, contact:

Ms. Nancy C. Lohrey, M.S., MT-ASCP
Program Director
Telephone: (301) 496-8580
Fax: (301) 402-4472
E-mail: Lohreyn@mail.nih.gov

For information regarding fiscal and/or budget issues, contact:

Grants Administration Branch
Phone: (301) 496-3179
Fax: (301) 496-8601

Back to Top